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Abstract
Objective: Phosphodiesterases (PDEs) negatively regulate the concentrations of cAMP and/or cGMP, which act as downstream second
messengers to the prostaglandins. PDE type-4 (PDE4) is selective for cAMP and is found in high concentrations in endothelial, epithelial, and
different blood cells. The aim of this study was to evaluate if PDI747, a novel selective inhibitor of PDE4, can restore pretransplant cAMP
levels and thereby posttransplant organ function after prolonged cold ischemia. Methods: Left lung transplantation was performed in pigs
(25–31 kg). Donor lungs were flushed with low potassium dextran glucose (LPDG) solution only (control, n ¼ 5)or, in addition with 1 mmol
of PDI747 (PDI747, n ¼ 5) and stored for 30 h at 1 8C. PDI747 animals further received a bolus of PDI747 (0.3 mg/kg) 15 min prior to
reperfusion and a continuous infusion (0.3 mg/kg per hour) during the 5 h after reperfusion. After occlusion of the right pulmonary arteries
and the right main bronchus, hemodynamic and gas exchange parameters and extravascular lung water (EVLW) levels of the transplanted
lung were assessed. Results: Two control animals died of severe lung edema leading to heart failure (control, n ¼ 3). One animal in the
treatment group was excluded due to a patent ductus arteriosus (PDI747, n ¼ 4). Gas exchange at the end of the experiment was restored to
normal levels in the PDI747 group (Pa, O2 47.6 ^ 11.2 kPa, Pa,CO2 6.4 ^ 1.8 kPa) but not in the control group (Pa, O2 7.7 ^ 2.9 kPa, Pa,
CO2 11.9 ^ 3.0 kPa, PPaO2 , 0.0001, PPa, CO2 ¼ 0.06). Extravascular lung water (EVLW) was normal in the PDI747 group (8.5 ^ 1.1 ml/kg)
and clearly elevated in the control group (16.2 ^ 5.6 ml/kg, P ¼ 0:007). Airway pressure in the PDI747 group was significantly lower than in
the control group (7.8 ^ 0.5 cm H2O vs. 11.3 ^ 0.6 cm H2O, respectively, P , 0:0001). The free radical mediated tissue injury measured by
lipid peroxidation (TBARS) was significantly reduced ðP ¼ 0:001Þ in the PDI747 group. Conclusions: With the inhibition of PDE4 with
PDI747 we achieved normal gas exchange, no posttransplant lung edema, normal airway pressures, and a reduced free radical injury after 30 h
of cold ischemia.
q 2003 Published by Elsevier B.V.
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1. Introduction
After lung transplantation, severe life-threatening graft
dysfunction occurs in 10–20% of patients and is mainly
caused by ischemia/reperfusion (I/R) injury, leading to
increased pulmonary vascular permeability, increased
airway pressures, and alveolar epithelial cell damage.
Edema, inflammation, neutrophil infiltration, intraparen-
chymal hemorrhage, necrosis, and apoptosis are some of the
histo-pathological markers of this injury. Despite intensive
research not all mechanisms are fully understood but
endothelial dysfunction has been shown to play an
important role. Past studies have also indicated that some
of the key factors and underlying mechanisms resulting in
graft dysfunction include oxygen free radicals [1], acti-
vation and migration of neutrophil granulocytes [2], and
activation of the complement system [3,11].
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In the early 1960s, inhibitors of the cyclic nucleotides
cAMP and cGMP, the cyclic nucleotide phosphodiesterases
(PDEs), were discovered [4]. PDEs are the critical enzymes
responsible for the degradation of cAMP and/or cGMP.
Thereby the synthesis of prostaglandins and nitric oxide
(NO) is modulated.
Nine different types of PDE (types 1–9) and several
subgroups (A, B, C, etc.) have been identified, but only the
properties of types 6–9 are well understood. Also, PDE4 has
been shown to be a selective inhibitor of cAMP. The concen-
trations of PDEs vary with different tissues. For example, in
human airway epithelial cells (hAEC) there are high amounts
of PDE types 1, 4, 5 and 7, and very little of types 2 and 3. In
addition to this, high activity of PDE4 was found in airway
smooth muscle cells [6]. In porcine airway epithelial cells
(pAEC) on the other hand, PDE types 4 (PDE4) and 5 have
the highest activity [7]. Several groups have investigated the
role of cAMP in the development of endothelial dysfunction
and have shown in vitro that inhibition of cAMP-consuming
reactions or stimulation of cAMP production results in
decreased endothelial leakage [5].
PDI747 is a new, selective, and potent inhibitor of PDE4.
Therefore, it reduces the decline in cAMP concentrations
during ischemia and possibly during reperfusion. Since
cAMP is a second messenger in the prostaglandin synthesis
pathway, the resulting increase in cAMP levels upon
PDI747 treatment will lead to a decrease in cellular
inflammatory responses and reduce the onset of lung
edema, while causing bronchodilatation [9]. Thus, we
hypothesize that the selective inhibition of PDE4 will
reduce ischemia/reperfusion injury after prolonged cold
ischemia.
2. Materials and methods
Ten weight-matched pairs of pigs (26–36 kg, aged 3–4
months) served as donors and recipients, with the heavier
pig used as the donor. Two groups were formed: the control
group (n ¼ 5) and the group treated with PDI747 (n ¼ 5),
and were studied in an alternating fashion. Harvest and
transplant of lungs were performed under non-sterile
conditions by the same surgeon.
2.1. Drug preparation and administration
PDI747 (4395 mg; Novartis Pharma AG, Switzerland)
was dissolved in 10 ml of 5% glucose solution. One milliter
of this solution was then added to 1000 ml Perfadex (LPDG,
Medisan Pharmaceuticals AB, Uppsala Sweden), resulting
in a concentration of 1 mmol/l. The recipient received a
bolus of PDI747 (0.3 mg/kg) 10 min prior to reperfusion and
was infused continuously (0.3 mg/kg) throughout the
observation period of 5 h.
All animal procedures were approved by the ethics
committee and were performed in accordance with
the ‘Guide for the Care and Use of Laboratory Animals’
(National Institutes of Health publication 85-23, revised
1985).
2.2. Donor procedure—explantation
The Heart–Lung-Block was harvested through a median
sternotomy from animals ventilated with 100% oxygen and
5 cm H2O of positive end-expiratory pressure (PEEP).
Heparin (300 IE/kg) was given via the aorta, and the
common pulmonary artery was canulated (Sarns, Inc, Ann
Arbor, MI). Two hundred and fifty micrograms of
prostaglandin E1 (PGE1) (Prostin VR Pediatric, Pharmacia
and Upjohn AG, Duebendorf) was injected into the common
pulmonary artery in order to achieve maximal vasodilata-
tion. The lungs were flushed with 1500 ml of cold (4 8C)
low potassium dextran glucose (LPDG) (Perfadex Medisan
Pharmaceuticals AB, Uppsala Sweden) with (PDI747
group) or without (control group) PDI747 at a pressure of
40 cm H2O.
The Heart–Lung-Block was stored semi-inflated with
100% oxygen in Perfadex solution at 1 8C for 30 h.
2.3. Recipient procedure—transplantation
The recipient pig was intubated and ventilated with
100% oxygen (FIO2: 1.0) and a PEEP of 5 during the whole
procedure. Tidal volume was 500 ml and was not changed
after occlusion of the right, native lung. Isoflurane
concentration varied between 0.2 and 1.5% depending on
the animals’ need.
Prior to surgery, the Swan–Ganz catheter was placed in
the right jugular vein and a fiber-optic thermistor-tipped
catheter (System Cold Z-021, Pulsion, Munich, Germany)
was placed via the carotid artery into the descending aorta.
A pneumonectomy on the left side was performed.
Briefly, the hemizygos vein was first resected and the left
pulmonary vein and the left artery were separated. The left
main bronchus and the carina were then exposed in order to
access the contralateral side. To assess graft function, only
the right main bronchus and the right pulmonary arteries
(right upper and main) were encircled from the left chest
cavity.
The left lung was then separated from the Heart–Lung-
Block. Prior to the implantation, the pig received heparin
intravenously (100 IE/kg). The anastomoses were com-
pleted with an everting mattress suture for the left
atrium (Prolene 5-0), a running suture for the pulmonary
artery (Prolene 5-0), and a running suture for the bronchus
(Prolene 4-0). A left atrial line (LA) was placed. A thoracic
drainage was introduced and the chest was closed
temporarily. One hour after reperfusion, the right lung was
excluded from ventilation and perfusion by occlusion of the
earlier encircled right main bronchus and the right
pulmonary arteries (arteries and bronchus) were occluded
to assess graft function only.
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2.4. Assessment
During the assessment period, the animals were under
general anesthesia. Blood pressure (systemic and pulmo-
nary), central venous pressure, oxygen saturation and the
expired CO2 were measured continuously. Extravascular
lung water (EVLW) levels, cardiac output, arterial and
venous blood gas parameters were measured at the
following times: prior to thoracotomy (T1), 10 min before
(T2) and 10 min after (T3) occlusion of the right side, and
then every hour (T4–T7).
2.5. Extravascular lung water (EVLW) levels
EVLW levels as a direct assessment of reperfusion
edema was measured as previously described [22]. A fiber
optic catheter (System Cold Z-021, Pulsion, Munich,
Germany) was advanced via the external carotid artery
into the descending aorta. The indicator bolus consisted of
two components: indo-cyanine green served as an intravas-
cular marker and ice cold 5% glucose as a thermal intra- and
extravascular indicator. The bolus was injected via the
external jugular vein with a temperature-controlled injector.
The dilution curves for the dye and temperature were
recorded simultaneously in the descending aorta with the
thermistor-tipped fiber-optic catheter. Thoracic intra- and
extravascular fluid volumes were determined based on the
measurement of the mean transit times for thermal and dye
indicators and of the decay time volumes calculated from
the indicator dilution curves. The lung water computer
(System Cold Z-021, Pulsion, Munich, Germany) deter-
mined the mean transit time for the thermal indicator and for
the dye indicator and calculated the total thermal volume
(ITTV), intrathoracic blood volume (ITBV), and extra-
vascular thermal volume (ETV). The ETV is calculated as
follows:
ETV ¼ ITTV 2 ITBV :
All measurements were made in triplicate. The mean values
were used for analysis.
Upon completion of the various analyses, the animals
were euthanized and the anastamoses were controlled and
samples of the transplanted lung were taken. From the snap
frozen samples, myeloperoxidase (MPO) activity and
thiobarbituric acid-reactive substance (TBARS) assays
were done.
2.6. Myeloperoxidase (MPO) assay
Quantitative MPO activity was determined as previously
described [12]. Enzyme activity is expressed as the change
in optical density unit per milligram of tissue protein (delta
OD/mg per min).
2.7. Thiobarbituric acid reactive substances (TBARS)
TBARS was measured in 10% wet wt. per volume
homogenate to determine the extent of lipid peroxidation in
the graft tissue. Aliquots (0.2 ml) of this homogenate were
added to tubes containing 0.2 ml of 8.1% sodium dodecyl
sulfate, 1.5 ml of 20% acetic acid solution adjusted to 3.5
pH with NaOH, and 1.5 ml of 0.8% solution of
thiobarbituric acid. The mixture was brought to a volume
of 4 ml by addition of distilled water heated at 95 8C for 60
min and then cooled with tap water. One milliliter of
distilled water and 5 ml of butanol/pyridine (15:1) were
added (all chemical by Fluka AG, Switzerland). The
solution was centrifuged at 4000 rpm for 10 min. The
absorbance of the upper layer was measured at 532 nm with
a spectrophotometer (Kadas 100, Dr. Lange AG Zurich,
Switzerland). The TBARS levels were determined by
reference to a standard curve of 1,1,3,3-tetramethoxypro-
pane (Sigma Chemicals, Switzerland), and the results were
expressed as nanomoles of malondialdehyde (MDA) per
gram of wet lung.
2.8. Statistics
All data were expressed as mean values ^ standard
deviation. Comparison between the two groups was
achieved using unpaired t-tests for the variables donor
weight, recipient weight, total ischemic time, MPO activity,
MDA (TBARS) and the hemodynamic variables at the end
of the observation period (T7). To evaluate the statistical
difference between the groups regarding EVLWI and the
gas exchange over the period T3–T7, an analysis of
variance for repeated measures was performed. In order to
get approximately normally distributed observations, log-
transformed data were used there. For all the analyses,
P-values less than 0.05 were considered significant.
Statistical analysis was made with SPSS for Windows.
3. Results
Two animals in the control group died shortly after
occlusion of the right side, due to pulmonary edema and
consecutive heart failure and thus were excluded from the
statistical analysis. In the treated group, one animal was also
excluded because of a wide-open ductus arteriosus, such
that the final sample sizes were n ¼ 3 for the control group
and n ¼ 4 for thePDI747 treated group.
No statistical differences were noted in donor weight
(control group 30.0 ^ 1.7 kg; PDI747 group 28.3 ^ 2.8 kg;
P ¼ 0:38), recipient weight (control group 29.3 ^ 3.1 kg;
PDI747 group 27.3 ^ 2.4 kg; P ¼ 0:35) and total ischemic
time (control group 1797 ^ 5 min; PDI747 group 1800 ^ 0
min; P ¼ 0:29).
EVLW in the transplanted lung at the end of the
assessment period (T7) was normal in the PDI747 group
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(8.5 ^ 1.2 ml/kg) and severely elevated in the control group
(16.2 ^ 5.6 ml/kg). During the assessment period (T3–T7),
the difference between the two groups was statistically
significant (P ¼ 0:007) (see Fig. 1).
At the end of the experiment, we found normal gas
exchange in the PDI747 group (PaO2 47.6 ^ 11.2 kPa;
PaCO2 6.4 ^ 1.8 kPa), whereas the control animals showed
poor oxygenation (PaO2 7.7 ^ 2.9 kPa) and extensive
hypercapnia (PaCO2 11.9 ^ 3.0 kPa). During the assessment
period (T3–T7), the difference between the two groups was
strongly significant for PaO2 (P , 0:0001) and borderline
significant for PaCO2 (P ¼ 0:06) (see Figs. 2 and 3).
Fig. 1. Means and standard deviations of extravascular lung water (EVLWI) for both groups during the whole period of observation. Time points T1–T7: prior
to thoracotomy (T1), 10 min before (T2) and 10 min after (T3) occlusion of the right side, and then every hour (T4–T7). In the control group the lungs
deteriorated by the end of the experiment while the treated pigs were stable throughout the experiment. Using an ANOVA for repeated measurements on
T3–T7 using log-transformed data, a significant difference was found between the groups (P ¼ 0:007).
Fig. 2. Means and standard deviations of Pa,O2 for both groups during the whole period of observation (T1–T7). Time points T1–T7: prior to thoracotomy
(T1), 10 min before (T2) and 10 min after (T3) occlusion of the right side, and then every hour (T4–T7). The gas exchange was almost normal in the treated
group and severely reduced in the control group. Using an ANOVA for repeated measurements on T3–T7 using log-transformed data, a significant difference
was found between the groups (P , 0.0001).
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At the end of the experiment, MPO activity was
1.10 ^ 0.09 in the control group and 1.06 ^ 0.20 in the
PDI747 group, and this difference was not significant
(P ¼ 0:75). A significant difference of MDA (TBARS)
between the groups was found (control group 0.19 ^ 0.03;
PDI747 group 0.03 ^ 0.02; P ¼ 0:001). Among the other
measured variables, we found significant differences
between the groups only for heartrate (control group
139.0 ^ 22.1; PDI747 group 180.5 ^ 7.6; P ¼ 0:02),
PINSP (control group 28.3 ^ 1.5 cm H2O; PDI747 group
18.5 ^ 1.7 cm H2O; P ¼ 0.001) and PMEAN (control group
11.3 ^ 0.6 H2O; PDI747 group 7.8 ^ 0.5 H2O;
P , 0.0001).
4. Discussion
In the present study, using a pig single-lung transplant
model, we demonstrated that donor and recipient treatment
with PDI747 protected the transplanted lung from I/R injury
induced by extended cold ischemia (30 h) and 5 h of
reperfusion. Our results showed significantly better graft
oxygenation, decreased edema, airway pressures, and lipid
peroxidation in the PDI747 treated group compared to the
control group.
The pathophysiology of I/R injury has been extensively
studied over the past 25 years and various mechanisms have
been described. The sequence of events following ischemic
injury can briefly be summarized as follows: a deficit in O2
supply results in decreased mitochondrial oxidative
phosphorylation and thus a depletion of ATP; one of
the consequences of decreased ATP is failure of ATP-
dependent pumps causing an accumulation of Naþ and H2O,
leading to the swelling of cells and culminating in edema of
the graft. Although reperfusion and reoxygenation are
essential for the ischemic tissue to regain function, it
increases the damage caused by ischemia. This phenomenon
is believed to involve the local generation of oxygen-
derived free radicals and the activation of leukocytes
interacting with endothelial cells. This interference finally
leads to cell-death, infiltration of activated inflammatory
cells, and development of a local inflammatory reaction
causing further edema and graft destruction.
The cyclic nucleotides cAMP and cGMP are second
messengers in the prostaglandin and NO synthesis path-
ways. During I/R, however, the production of both second
messengers is attenuated. Comparing the relative import-
ance of both the pathways, Bhabra et al. demonstrated in an
ex-vivo model of lung preservation that the failure of the
NO/cGMP pathway is more detrimental than the failure of
the prostaglandin/cAMP pathway [10,14]. Past experi-
mental work done by our group supports these findings.
Schmid et al. showed that with the addition of tetrahy-
drobiopterin, a cofactor for NO synthase, posttransplant
edema was reduced [15]. With the intravenous application
of 8-Br-cGMP, an analogue of cGMP, Hillinger et al.
showed that I/R injury was reduced with a decrease in
edema and free radical injury [16]. Lugnier et al. demon-
strated a cross talk between PDEs and NO leading to
upregulated NO production upon PDE4 inhibition [24].
Nevertheless, there is much evidence that normal to high
levels of intracellular cAMP are associated with a limited
Fig. 3. Means and standard deviations of Pa,CO2 for both groups during the whole period of observation (T1–T7). Time points T1–T7: prior to thoracotomy
(T1), 10 min before (T2) and 10 min after (T3) occlusion of the right side, and then every hour (T4–T7). Pigs in the control group were close to Pa,CO2-narcosis
whereas the treated pigs had only a slight increase in Pa,CO2. Using an ANOVA for repeated measurements on T3–T7 using log-transformed data, this
difference between the groups was borderline significant (P ¼ 0:06).
A.E. Dutly et al. / European Journal of Cardio-thoracic Surgery 24 (2003) 594–600598
response of inflammatory cells such as neutrophils, mono-
cytes, macrophages, dendritic cells, and lymphocytes
[8,25]. The exact mechanisms by which cAMP modulates
cell function are not completely understood but appear to
depend on the activation of protein kinase A and the
subsequent phosphorylation of hydroxy-amino acid
residues.
In transplanted organs I/R injury has also been shown to
activate antigen-dependent reactions. Hestek et al. showed
the anti-inflammatory effect of PDE4 inhibitor on a T cell
and dendritic cell level [25]. Experimental and clinical data
suggest that I/R injury increases graft immunogenicity by
upregulating MHC class I and II antigens resulting in an
increased incidence of acute rejection episodes and early
graft loss [13]. Schade et al. tested several PDE4-inhibitors
of a newer generation for their immunosuppressive proper-
ties [23], which all showed limited protection against
epithelial disturbance, infiltration of immune cells, and
luminal obliteration. Some of the tested inhibitors, such as
Cilomilast (Ariflo) and Roflumilast, exhibited a strong anti-
proliferative effect on fibroblasts, suggesting a possible
benefit in preventing against the development of obliterative
bronchiolitis.
The different PDE types modulate cAMP and/or cGMP
levels differently depending on cell types. PDE4 is selective
for cAMP and several authors have shown high levels of
PDE4 not only in inflammatory cells but also in epithelial
and endothelial cells, in the matrix of the pulmonary
arteries, and in the bronchi [9,17,18]. In an in-vitro study of
perfused rat lung, Held et al. showed a partial reversibility
of endothelin-1-induced vasoconstriction and broncho-
constriction with the PDE4 inhibitor, Rolipram [19].
In an orthotopic rat lung transplantation model, Pinsky
and Stern found a dose-dependent improvement of arterial
oxygenation, a reduction in pulmonary arterial resistance
and a subsequent increase in arterial flow upon treatment
with a PDE4 inhibitor. Rabe et al. demonstrated the effects
of several different PDE inhibitors in causing relaxation of
human pulmonary arteries [17]. At dosages up to 1 mg/kg
i.v., only minor changes in heart rate, arterial blood pressure
and cardiac output were seen. This, however, is in contrast
to our findings. In our study, the animals were treated with
0.3 mg/kg per hour PDI747, which caused a significant
increase in heart rate (P ¼ 0:02) but no significant changes
in blood pressure. The reduction of inspiratory airway
pressure after treatment with a PDE4 inhibitor is well
documented and reflects the effect on inflammatory cells as
well as on airway smooth muscle cells [9].
Unfortunately, in rats the pharmacological side effects of
arthritis and periarthritis exist, as have been shown for other
PDE inhibitors such as Rolipram and Zaprinast [20,21]. For
PDI747 Vogel et al. also observed segmental vasculitis after
topical administration (non-published data from Novartis).
These results caused disclosure of the research on PDI747.
In summary, in this experimental model where the donor
lungs and recipients were treated with PDI747, we achieved
reduced airway pressures, lung edema, and excellent gas
exchange after prolonged cold ischemia.
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